Switzerland-based generic pharmaceuticals and biosimilars company, Sandoz has invested $50.5m (€50m) to open a new production facility in Kundl, Austria.
The 3,000m2 manufacturing area allows for the production of an additional one billion penicillin tablets while also doubling the output of powder oral suspension (POS), primarily used in paediatric medicines. The new plant and automated manufacturing lines also add 20% to its current annual production capacity of 200 million packages.
Go deeper with GlobalData
Richard Saynor, CEO of Sandoz, said: “Kundl, as the hub and centre of our antibiotic production, is a true lighthouse project when it comes to the security of antibiotic supply. This investment is our contribution to fighting shortages and increasing access for patients. To be successful in the future, we need to join forces across healthcare systems and build a sustainable market environment for generic medicines, focused on what is best for patients.”
Part of its European-based production network, the opening of the new facility is part of a €200m investment into the site in Kundl, to upgrade penicillin API manufacturing and increase the output of finished products.
Headquartered in Basel, Sandoz Group AG develops, manufactures, distributes, and sells a range of prescription medicines, proteins, and biosimilars worldwide. It has over 20,000 employees worldwide.
